JP2020534828A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020534828A5 JP2020534828A5 JP2020516422A JP2020516422A JP2020534828A5 JP 2020534828 A5 JP2020534828 A5 JP 2020534828A5 JP 2020516422 A JP2020516422 A JP 2020516422A JP 2020516422 A JP2020516422 A JP 2020516422A JP 2020534828 A5 JP2020534828 A5 JP 2020534828A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- ile
- trp
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001413 amino acids Chemical group 0.000 claims 213
- 108090000765 processed proteins & peptides Proteins 0.000 claims 81
- 229920001184 polypeptide Polymers 0.000 claims 79
- 102000004196 processed proteins & peptides Human genes 0.000 claims 79
- 235000001014 amino acid Nutrition 0.000 claims 51
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims 49
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 33
- 108091008874 T cell receptors Proteins 0.000 claims 21
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 21
- 210000004027 cell Anatomy 0.000 claims 14
- 239000008194 pharmaceutical composition Substances 0.000 claims 13
- 235000018102 proteins Nutrition 0.000 claims 12
- 102000004169 proteins and genes Human genes 0.000 claims 12
- 108090000623 proteins and genes Proteins 0.000 claims 12
- 102000016914 ras Proteins Human genes 0.000 claims 9
- 238000000034 method Methods 0.000 claims 8
- 206010028980 Neoplasm Diseases 0.000 claims 7
- 201000011510 cancer Diseases 0.000 claims 7
- 101000584612 Homo sapiens GTPase KRas Proteins 0.000 claims 6
- 239000013604 expression vector Substances 0.000 claims 6
- 102000039446 nucleic acids Human genes 0.000 claims 6
- 108020004707 nucleic acids Proteins 0.000 claims 6
- 150000007523 nucleic acids Chemical class 0.000 claims 6
- 238000003259 recombinant expression Methods 0.000 claims 6
- 101000584633 Homo sapiens GTPase HRas Proteins 0.000 claims 5
- 101000744505 Homo sapiens GTPase NRas Proteins 0.000 claims 5
- 108700020796 Oncogene Proteins 0.000 claims 5
- 102000043600 human HRAS Human genes 0.000 claims 5
- 102000049555 human KRAS Human genes 0.000 claims 5
- 102000047526 human NRAS Human genes 0.000 claims 5
- 239000004471 Glycine Substances 0.000 claims 4
- 241000124008 Mammalia Species 0.000 claims 4
- 241000713810 Rat sarcoma virus Species 0.000 claims 4
- 238000006467 substitution reaction Methods 0.000 claims 4
- 125000000998 L-alanino group Chemical group [H]N([*])[C@](C([H])([H])[H])([H])C(=O)O[H] 0.000 claims 3
- 238000002955 isolation Methods 0.000 claims 3
- 102100040485 HLA class II histocompatibility antigen, DRB1 beta chain Human genes 0.000 claims 2
- 108010039343 HLA-DRB1 Chains Proteins 0.000 claims 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims 2
- 206010029260 Neuroblastoma Diseases 0.000 claims 2
- 239000000427 antigen Substances 0.000 claims 2
- 108091007433 antigens Proteins 0.000 claims 2
- 102000036639 antigens Human genes 0.000 claims 2
- 235000018417 cysteine Nutrition 0.000 claims 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 2
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 claims 2
- 239000004474 valine Substances 0.000 claims 2
- 102100030708 GTPase KRas Human genes 0.000 claims 1
- 108010058597 HLA-DR Antigens Proteins 0.000 claims 1
- 102000006354 HLA-DR Antigens Human genes 0.000 claims 1
- 102210029654 HLA-DRB1*07:01 Human genes 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 210000004696 endometrium Anatomy 0.000 claims 1
- 150000002333 glycines Chemical group 0.000 claims 1
- 210000000265 leukocyte Anatomy 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 201000001514 prostate carcinoma Diseases 0.000 claims 1
- 238000000746 purification Methods 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762560930P | 2017-09-20 | 2017-09-20 | |
| US62/560,930 | 2017-09-20 | ||
| PCT/US2018/051641 WO2019060349A1 (en) | 2017-09-20 | 2018-09-19 | CLASS II HLA RESTRICTED T LYMPHOCYTE RECEPTORS AGAINST KRAS MUTATED |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020534828A JP2020534828A (ja) | 2020-12-03 |
| JP2020534828A5 true JP2020534828A5 (enExample) | 2021-11-11 |
| JP7256794B2 JP7256794B2 (ja) | 2023-04-12 |
Family
ID=63963389
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020516422A Active JP7256794B2 (ja) | 2017-09-20 | 2018-09-19 | 変異型ｒａｓに対するｈｌａクラスｉｉ拘束性ｔ細胞受容体 |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US11306132B2 (enExample) |
| EP (1) | EP3684799B1 (enExample) |
| JP (1) | JP7256794B2 (enExample) |
| KR (2) | KR20250037592A (enExample) |
| CN (2) | CN120082603A (enExample) |
| AR (1) | AR112902A1 (enExample) |
| AU (2) | AU2018335274B2 (enExample) |
| BR (1) | BR112020005469A2 (enExample) |
| CA (1) | CA3076339A1 (enExample) |
| CR (2) | CR20240019A (enExample) |
| EA (1) | EA202090652A1 (enExample) |
| IL (1) | IL273254B2 (enExample) |
| MA (1) | MA50180A (enExample) |
| MX (2) | MX2020003117A (enExample) |
| SG (1) | SG11202002425PA (enExample) |
| TW (1) | TWI825029B (enExample) |
| WO (1) | WO2019060349A1 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201700621D0 (en) | 2017-01-13 | 2017-03-01 | Guest Ryan Dominic | Method,device and kit for the aseptic isolation,enrichment and stabilsation of cells from mammalian solid tissue |
| CA3127673A1 (en) * | 2019-01-25 | 2020-07-30 | The Trustees Of The University Of Pennsylvania | Compositions and methods for targeting mutant ras |
| US20220291215A1 (en) * | 2019-07-30 | 2022-09-15 | University Health Network | Methods of identifying t cell receptors |
| CN112759641B (zh) * | 2019-11-01 | 2023-01-20 | 香雪生命科学技术（广东）有限公司 | 一种识别Kras G12V的高亲和力TCR |
| JP2023507432A (ja) | 2019-12-20 | 2023-02-22 | インスティル バイオ （ユーケイ） リミテッド | 腫瘍浸潤リンパ球を単離するためのデバイスおよび方法ならびにそれらの使用 |
| MX2022009825A (es) * | 2020-02-14 | 2022-10-13 | Us Health | Receptores de células t restringidas por hla de la clase i contra ras con mutación g12v. |
| US20230090247A1 (en) * | 2020-02-19 | 2023-03-23 | Aelin Therapeutics | Molecules targeting ras protein |
| US20230159614A1 (en) * | 2020-02-26 | 2023-05-25 | The United States Of America,As Represented By The Secretary,Department Of Health And Human Services | Hla class ii-restricted t cell receptors against ras with g12v mutation |
| US20230312672A1 (en) * | 2020-06-24 | 2023-10-05 | The United States Of America,As Represented By The Secretary,Department Of Health And Human Services | Hla class i-restricted t cell receptors against cd20 |
| CA3185241A1 (en) | 2020-07-13 | 2022-01-20 | Noam LEVIN | Hla class ii?restricted drb t cell receptors against ras with g12d mutation |
| WO2022015922A1 (en) * | 2020-07-16 | 2022-01-20 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Hla class ii-restricted drb t cell receptors against ras with g12v mutation |
| CN112300269B (zh) * | 2020-09-29 | 2022-12-09 | 中国科学院微生物研究所 | Kras突变特异性t细胞受体筛选及抗肿瘤用途 |
| AU2021351710A1 (en) * | 2020-10-02 | 2023-06-08 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Hla class ii-restricted dq t cell receptors against ras with g13d mutation |
| JP2023550515A (ja) * | 2020-11-24 | 2023-12-01 | シャンハイ、ケンパーソー、バイオテクノロジー、カンパニー、リミテッド | Ｒａｓ突然変異体エピトープペプチドおよびｒａｓ突然変異体を認識するｔ細胞受容体 |
| JP2024507929A (ja) | 2021-02-25 | 2024-02-21 | アラウノス セラピューティクス インコーポレイテッド | 多シストロン性発現カセットを含む組換えベクター及びそれらの使用方法 |
| WO2023150562A1 (en) | 2022-02-01 | 2023-08-10 | Alaunos Therapeutics, Inc. | Methods for activation and expansion of t cells |
| CN114835800B (zh) * | 2022-05-27 | 2023-10-13 | 重庆医科大学 | Tcr或其抗原结合片段及其应用 |
| CN117264043B (zh) * | 2022-06-14 | 2024-05-10 | 上海镔铁生物科技有限责任公司 | 靶向kras g12v突变多肽的t细胞受体及其用途 |
| WO2024072954A1 (en) * | 2022-09-29 | 2024-04-04 | Jerome Canady Research Institute for Advanced Biological and Technological Sciences | Cold atmopsheric plasma treated pan-cancer epitope peptide within the collagen type vi a-3 (col6a3) protein as cancer vaccine |
| WO2026019786A1 (en) * | 2024-07-16 | 2026-01-22 | Board Of Regents, The University Of Texas System | Peptides and engineered t cell receptors targeting brachyury antigen and methods of use |
| WO2026024602A2 (en) * | 2024-07-22 | 2026-01-29 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | T cell receptors against ras with g12d, g12v, g13d or q61r mutation |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8034334B2 (en) | 2002-09-06 | 2011-10-11 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Immunotherapy with in vitro-selected antigen-specific lymphocytes after non-myeloablative lymphodepleting chemotherapy |
| GB0328363D0 (en) * | 2003-12-06 | 2004-01-14 | Imp College Innovations Ltd | Therapeutically useful molecules |
| US8383099B2 (en) | 2009-08-28 | 2013-02-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Adoptive cell therapy with young T cells |
| US20120244133A1 (en) | 2011-03-22 | 2012-09-27 | The United States of America, as represented by the Secretary, Department of Health and | Methods of growing tumor infiltrating lymphocytes in gas-permeable containers |
| ES2924709T3 (es) | 2014-10-02 | 2022-10-10 | Us Health | Métodos de aislamiento de receptores de células T que tienen especificidad antigénica para una mutación específica de cáncer |
| SG10201913978RA (en) * | 2014-11-26 | 2020-03-30 | The United States Of America As Represented By The Secretary | Anti-mutated kras t cell receptors |
| JP6869947B2 (ja) * | 2015-07-22 | 2021-05-12 | アラクセス ファーマ エルエルシー | 置換キナゾリン化合物ならびにそのｇ１２ｃ変異ｋｒａｓ、ｈｒａｓおよび／またはｎｒａｓタンパク質の阻害剤としての使用 |
| SG10201913868XA (en) * | 2015-09-15 | 2020-03-30 | The United States Of America As Represented By The Secretary | T cell receptors recognizing hla-cw8 restricted mutated kras |
| SG11201900654QA (en) | 2016-08-02 | 2019-02-27 | Us Health | Anti-kras-g12d t cell receptors |
-
2018
- 2018-09-19 AU AU2018335274A patent/AU2018335274B2/en active Active
- 2018-09-19 KR KR1020257006999A patent/KR20250037592A/ko active Pending
- 2018-09-19 US US16/135,231 patent/US11306132B2/en active Active
- 2018-09-19 WO PCT/US2018/051641 patent/WO2019060349A1/en not_active Ceased
- 2018-09-19 EP EP18792591.2A patent/EP3684799B1/en active Active
- 2018-09-19 JP JP2020516422A patent/JP7256794B2/ja active Active
- 2018-09-19 CR CR20240019A patent/CR20240019A/es unknown
- 2018-09-19 MA MA050180A patent/MA50180A/fr unknown
- 2018-09-19 CN CN202510245856.3A patent/CN120082603A/zh active Pending
- 2018-09-19 EA EA202090652A patent/EA202090652A1/ru unknown
- 2018-09-19 BR BR112020005469-0A patent/BR112020005469A2/pt unknown
- 2018-09-19 CR CR20200150A patent/CR20200150A/es unknown
- 2018-09-19 SG SG11202002425PA patent/SG11202002425PA/en unknown
- 2018-09-19 KR KR1020207011112A patent/KR102777370B1/ko active Active
- 2018-09-19 CN CN201880060535.4A patent/CN111201237B/zh active Active
- 2018-09-19 CA CA3076339A patent/CA3076339A1/en active Pending
- 2018-09-19 MX MX2020003117A patent/MX2020003117A/es unknown
- 2018-09-19 IL IL273254A patent/IL273254B2/en unknown
- 2018-09-20 AR ARP180102695A patent/AR112902A1/es unknown
- 2018-09-20 TW TW107133221A patent/TWI825029B/zh active
-
2020
- 2020-03-19 MX MX2024004610A patent/MX2024004610A/es unknown
-
2022
- 2022-03-11 US US17/692,787 patent/US12304940B2/en active Active
-
2025
- 2025-04-09 AU AU2025202532A patent/AU2025202532A1/en active Pending
- 2025-04-22 US US19/185,924 patent/US20250250318A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021505136A5 (enExample) | ||
| Ho et al. | Bacteriophage λ protein c II binds promoters on the opposite face of the DNA helix from RNA polymerase | |
| IL273254B2 (en) | HLA type II-restricted T cell receptors against RAS | |
| JP2015535816A5 (enExample) | ||
| JP2018535647A5 (enExample) | ||
| EP1423140A2 (en) | Compositions and methods for modulation of immune responses | |
| CN113179631A (zh) | 通过临近使能反应疗法开发的共价蛋白质药物 | |
| JP2022523024A5 (enExample) | ||
| US20130203163A1 (en) | Promiscuous pap cd4 t cell epitopes | |
| Sauter et al. | A part of the VP4 capsid protein exhibited by coxsackievirus B4 E2 is the target of antibodies contained in plasma from patients with type 1 diabetes | |
| JP2023534241A5 (enExample) | ||
| JP2022535458A (ja) | Ｂ型肝炎ウイルス特異的なｔ細胞応答 | |
| US8658177B2 (en) | Promiscuous HER-2/Neu CD4 T cell epitopes | |
| WO2015072750A1 (ko) | 항염증 활성을 갖는 펩티드 및 이를 포함하는 조성물 | |
| JP2023535366A5 (enExample) | ||
| NZ805541A (en) | Hla class i-restricted t cell receptors against mutated ras | |
| JP2023535366A (ja) | Ｇ１２ｖ変異を有するｒａｓに対するｈｌａクラスｉｉ拘束性ｄｒｂ ｔ細胞受容体 | |
| KR100455902B1 (ko) | Ｂ형 간염 바이러스 표면단백질 프리에스-1 유래의 펩타이드 | |
| AU2002324581A1 (en) | Compositions and methods for modulation of immune responses | |
| NZ779633A (en) | T cell receptors recognizing hla-cw8 restricted mutated kras | |
| NZ779633B2 (en) | T cell receptors recognizing hla-cw8 restricted mutated kras |